Dyne Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Selling, General & Admin	31.4	28.2	28.72	13.45	2.79	0.52
Research & Development	210.76	142.76	121.31	45.2	11.04	4.28
Operating Expenses	242.16	170.96	150.03	58.65	13.83	4.8
Operating Income	-242.16	-170.96	-150.03	-58.65	-13.83	-4.8
Interest Expense / Income	0	0	0	0.4	0	0
Other Expense / Income	-6.23	-2.86	-0.73	0.39	1.03	0.02
Pretax Income	-235.94	-168.1	-149.29	-59.44	-14.86	-4.81
Net Income	-235.94	-168.1	-149.29	-59.44	-14.86	-4.81
Shares Outstanding (Basic)	60	52	51	14	2	0
Shares Outstanding (Diluted)	60	52	51	14	2	0
Shares Change	14.83%	2.12%	253.54%	489.30%	415.25%	-
EPS (Basic)	-3.95	-3.23	-2.93	-4.13	-6.08	-10.15
EPS (Diluted)	-3.95	-3.23	-2.93	-4.13	-6.08	-10.15
Free Cash Flow	-188.89	-156.71	-123.18	-47.67	-13.48	-4.3
Free Cash Flow Per Share	-3.17	-3.02	-2.42	-3.31	-5.52	-9.06
EBITDA	-233.48	-164.75	-148.95	-58.34	-14.59	-4.79
Depreciation & Amortization	2.46	3.35	0.34	0.7	0.27	0.02
EBIT	-235.94	-168.1	-149.29	-59.04	-14.86	-4.81

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).